This breakthrough in the advancement of transdermal capability would mean ‘smart patches’ could be used to detect certain biomarkers within skin interstitial fluid (ISF).
These patches are comprised of arrays microneedles designed to break the skin barrier – in a minimally invasive manner - and monitor the biomarkers of clinical significance. They can be self-administered for point-of-care diagnosis at GP practices or at home.
In a statement, Swansea’s Dr Sanjiv Sharma, who previously developed the world’s first COVID-19 ‘smart patch’, said: “The skin is the largest organ in the body – it contains more ISF than the total volume of blood. This fluid is an ultrafiltrate of blood and holds biomarkers that complement other biofluids such as sweat, saliva, and urine. It can be sampled in a minimally invasive manner and used either for point-of-care testing or real time using microneedle devices.
MORE FROM MEDICAL & HEALTHCARE
“We employed microneedle array-based biosensing patches as wearable transdermal sensors to detect the proinflammatory cytokine IL-6. IL-6 is present in the skin ISF with other cytokines and is implicated in many clinical states including neurodegenerative diseases and fatal pneumonia from SARSCoV 2. We have been able to detect IL-6 at concentrations as low as 1pg/mL in synthetic skin ISF, indicating its utility for routine point of care, bloodless measurements in simpler settings, worldwide.”
Dr Sharma continued: “The devices we developed are scalable, and the resulting sensor has a short measurement time [six minutes], with high accuracy and a low limit of detection. This new diagnostic tool, for screening of inflammatory biomarkers in point of care testing, will see the skin act as a window to the body and vital organs such as the brain.”
This work, which has been published by the American Chemical Society, was done in collaboration with Biomark, ISEP, Porto, Portugal.
Co-author, Felismina Moreira from the School of Engineering, Polytechnic Institute, Portugal said: “Biomark ISEP Porto have pioneered applications of molecular imprinted polymers [MIPS] and extended them to different healthcare applications. Together with Swansea's expertise in transdermal diagnostics we have demonstrated that the MIPs together with the microneedle arrays offers a fantastic platform for the development of point of care devices for bloodless testing. These can be extended to diagnostics for cardiovascular, cancer and neurodegenerative disorders.”
Swansea University is currently working with its research partners in UK, Portugal, France and Japan towards furthering the field of transdermal diagnostics and extending it for the development of diagnostic devices for numerous healthcare applications.
英國鐵路公司如何推動凈零排放
It would be better if the trains had good coverage of the country. Large areas have no easy connection and so cars (or buses?) and lorries are still...